Association of mTOR Pathway Markers and Clinical Outcomes in Patients with Intermediate-/High-risk Prostate Cancer: Long-Term Analysis

Academic Article

Abstract

  • © 2019 Elsevier Inc. The mammalian target of rapamycin (mTOR) pathway is up-regulated in prostate cancer. In this study, prostate tumor tissue expression of downstream molecule of the mTOR pathway, especially pS6 and mTOR, were associated with the outcome of patients with intermediate-/high-risk prostate cancer. These molecules could serve as potential surrogate markers for treatment selection when evaluating inhibitors of the mTOR pathway in prostate cancer.
  • Published In

    Digital Object Identifier (doi)

    Author List

  • Barata PC; Magi-Galluzzi C; Gupta R; Dreicer R; Klein EA; Garcia JA
  • Start Page

  • 366
  • End Page

  • 372
  • Volume

  • 17
  • Issue

  • 5